
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 4)

ALLOGENE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock
(Title of Class of Securities)

019770 10 6
(CUSIP Number)

December 31, 2023
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

| | | |
|--|---|--|
| 1 | Names of Reporting Persons Arie Belldegrün, M.D. | |
| 2 | Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization United States of America and Israel | |
| Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power 3,192,581 Shares (1) |
| | 6 | Shared Voting Power 6,703,323 Shares (2) |
| | 7 | Sole Dispositive Power 3,192,581 Shares (1) |
| | 8 | Shared Dispositive Power 6,703,323 Shares (2) |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 9,895,903 Shares | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="checkbox"/> | |
| 11 | Percent of Class Represented by Amount in Row (9) 5.8% (3) | |
| 12 | Type of Reporting Person IN | |

- (1) Includes 2,847,489 shares of common stock issuable within 60 days of December 31, 2023 upon the exercise of stock options held by the Reporting Person and 142,150 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2023.
- (2) Includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrün and Rebecka Belldegrün, (b) 195,039 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrün and Rebecka Belldegrün and (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager, of which Dr. Belldegrün is a Senior Managing Director. Dr. Belldegrün disclaims beneficial ownership of the shares held by Vida, except to the extent of any pecuniary interest therein.
- (3) This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

| | | |
|---|---|--|
| 1 | Names of Reporting Persons Bellco Legacy IV, LLC | |
| 2 | Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization Delaware | |
| Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power 0 Shares |
| | 6 | Shared Voting Power 4,710,120 Shares |
| | 7 | Sole Dispositive Power 0 Shares |
| | 8 | Shared Dispositive Power 4,710,120 Shares |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 4,710,120 Shares | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="checkbox"/> | |
| 11 | Percent of Class Represented by Amount in Row (9) 2.8% (1) | |
| 12 | Type of Reporting Person OO | |

- (1) This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

| | | |
|--|---|--|
| 1 | Names of Reporting Persons Bellco Legacy LLC | |
| 2 | Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization Delaware | |
| Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power 0 Shares |
| | 6 | Shared Voting Power 195,039 Shares |
| | 7 | Sole Dispositive Power 0 Shares |
| | 8 | Shared Dispositive Power 195,039 Shares |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 195,039 Shares | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="checkbox"/> | |
| 11 | Percent of Class Represented by Amount in Row (9) 0.1% (1) | |
| 12 | Type of Reporting Person OO | |

- (1) This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

| | | |
|---|---|--|
| 1 | Names of Reporting Persons Vida Ventures LLC | |
| 2 | Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> (b) <input type="checkbox"/> | |
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization Nevada | |
| Number of Shares Beneficially Owned by Each Reporting Person With: | 5 | Sole Voting Power 0 Shares |
| | 6 | Shared Voting Power 1,798,163 Shares |
| | 7 | Sole Dispositive Power 0 Shares |
| | 8 | Shared Dispositive Power 1,798,163 Shares |
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 1,798,163 Shares | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="checkbox"/> | |
| 11 | Percent of Class Represented by Amount in Row (9) 1.1% (1) | |
| 12 | Type of Reporting Person OO | |

- (1) This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

- Item 1(a).** Name of Issuer:
Allogene Therapeutics, Inc.
- Item 1(b).** Address of Issuer's Principal Executive Offices:
210 East Grand Avenue
South San Francisco, CA 94080
- Item 2(a).** Names of Persons Filing:
Arie Beldegrun, M.D.
Bellco Legacy IV LLC
Bellco Legacy LLC
Vida Ventures LLC
- Item 2(b).** Address of Principal Business Office, or, if none, Residence:
The address of Arie Beldegrun, M.D. is:
10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
The address of Bellco Legacy IV LLC and Bellco Legacy LLC is:
10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
The address of Vida Ventures LLC is:
40 Broad Street, #201, Boston, MA 02109
- Item 2(c).** Citizenship:
Arie Beldegrun: USA and Israel
Bellco Legacy IV LLC: Delaware
Bellco Legacy LLC: Delaware
Vida Ventures LLC: Nevada
- Item 2(d).** Title of Class of Securities:
Common Stock
- Item 2(e).** CUSIP No.:
019770 10 6
- Item 3.** Not Applicable.

Item 4. Ownership

The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2023. This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

| Reporting Person | Shares Held Directly | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Beneficial Ownership | Percentage of Class(1) |
|-------------------------|-----------------------------|--------------------------|----------------------------|-------------------------------|---------------------------------|-----------------------------|-------------------------------|
| Arie Beldegrun | 3,192,581 | 3,192,581 | 6,703,323 | 3,192,581 | 6,703,323 | 9,895,903 | 5.8% |
| Bellco Legacy IV, LLC | 4,710,120 | 0 | 4,710,120 | 0 | 4,710,120 | 4,710,120 | 2.8% |
| Bellco Legacy LLC | 195,039 | 0 | 195,039 | 0 | 195,039 | 195,039 | 0.1% |
| Vida Ventures LLC | 1,798,163 | 0 | 1,798,163 | 0 | 1,798,163 | 1,798,163 | 1.1% |

(1) This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 2, 2023.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

/s/ Arie Beldegrun

Arie Beldegrun, M.D.

Bellco Legacy IV LLC

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Manager

Bellco Legacy LLC

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Manager

Vida Ventures LLC

By: VV Manager LLC, its Manager

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Senior Managing Director

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of Allogene Therapeutics, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which, taken together, shall constitute one and the same instrument.

Dated: February 14, 2024

/s/ Arie Beldegrun

Arie Beldegrun, M.D.

Bellco Legacy IV LLC

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Manager

Bellco Legacy LLC

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Manager

Vida Ventures LLC

By: VV Manager LLC, its Manager

By: /s/ Arie Beldegrun

Name: Arie Beldegrun, Senior Managing Director